Global Idhifa Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Idhifa Market Research Report 2024
Idhifa is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test
According to Mr Accuracy reports new survey, global Idhifa market is projected to reach US$ 125.9 million in 2029, increasing from US$ 78 million in 2022, with the CAGR of 7.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Idhifa market research.
Enasidenib is a targeted therapy used to treat relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. Its efficacy in inhibiting the mutated IDH2 enzyme and inducing remission has driven market growth. The limited treatment options for this specific subset of AML contribute to its niche status. However, challenges include potential side effects and the need for genetic testing to identify eligible patients. The market competition is relatively small, as Enasidenib remains a targeted therapy for a specific AML subgroup. Despite challenges, the Enasidenib market offers potential for growth as healthcare providers seek effective treatments for patients with IDH2-mutated AML. Continued research and clinical advancements can further drive market expansion.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Idhifa market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Bristol Myers Squibb
Segment by Type
50mg
100mg
Hospital
Pharmacy
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Idhifa report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Idhifa market is projected to reach US$ 125.9 million in 2029, increasing from US$ 78 million in 2022, with the CAGR of 7.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Idhifa market research.
Enasidenib is a targeted therapy used to treat relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. Its efficacy in inhibiting the mutated IDH2 enzyme and inducing remission has driven market growth. The limited treatment options for this specific subset of AML contribute to its niche status. However, challenges include potential side effects and the need for genetic testing to identify eligible patients. The market competition is relatively small, as Enasidenib remains a targeted therapy for a specific AML subgroup. Despite challenges, the Enasidenib market offers potential for growth as healthcare providers seek effective treatments for patients with IDH2-mutated AML. Continued research and clinical advancements can further drive market expansion.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Idhifa market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bristol Myers Squibb
Segment by Type
50mg
100mg
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Idhifa report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices